METiS Pharmaceuticals ^Companies

development of programmable nucleic acid drugs and nucleic acid delivery design. METiS Pharmaceuticals has achieved significant milestones in the field of drug formulation, with a focus on creating innovative delivery materials and selecting optimal drug candidates. The company's core technology platforms, AiLNP, AiRNA, and AiTEM, enable the development of best-in-class therapies for various diseases. METiS actively seeks collaborations with biotechnology companies, pharmaceutical companies, and academic institutions worldwide to further advance their research and development efforts. With a strong pipeline of over 10 drug candidates, METiS Pharmaceuticals is poised to make a significant impact in the pharmaceutical industry.